Skip to main content
. Author manuscript; available in PMC: 2016 Jul 12.
Published in final edited form as: Chin Clin Oncol. 2015 Mar;4(1):11. doi: 10.3978/j.issn.2304-3865.2015.02.01

Table 3.

Recent and active randomized controlled trials for PCNSL

Trial Regimen Status
G-PCNSL-SG1 HD-MTX-based induction +/− WBRT consolidation Thiel et al. (81)
IELSG-20 HD-MTX +/− HD-Ara-C- > WBRT consolidation Ferreri et al. (80)
IELSG-32 Myeloablative vs. WBRT consolidation Accrual complete
Alliance 51101 Intensive vs. myeloablative consolidation Active
PRECIS Myeloablative vs. WBRT consolidation Active
Matrix/IELSG43 Intensive vs. myeloablative consolidation Active

CALGB (Alliance) 51101 compares dose-intensive consolidation with infusional etoposide plus high-dose cytarabine (EA) with high-dose chemotherapy (BCNU plus thiotepa), supported by autologous stem cell transplant (7). The MATRIX/IELSG43 evaluates high-dose chemotherapy, BCNU plus thiotepa supported by autologous stem cell transplant in comparison to a dose-intensive consolidation regimen consisting of dexamethasone, etoposide, carboplatin and ifosfamide). HD-MTX, high-dose methotrexate; WBRT, whole brain radiotherapy; Ara-C, cytarabine.